Omnipod5 Real-World Data from the First Pediatric Users’ Universal Coverage Under the UK National Health Service
Authors' conclusion
These findings highlight the Omnipod5 system's safety and effectiveness in improving glycemic control for children and young people (CYP) with type 1 diabetes in a real-world NHS setting.
Study context
- Population
- Children <18 years with T1D started on Omnipod5 (Aug 2023–Jan 2024), two teaching hospital-based centres, North West England; 46% male, mean age 7.1 years (SD 4.3), 80% White, diabetes duration 4.4 years (SD 3.9); prior MDI 54%, nonintegrated pump 41%, other hybrid closed-loop (HCL) 5%
- Participants
- 144 children
- Exposure
- Omnipod5 HCL vs pre-initiation baseline
- Outcome
- HbA1c
- Follow-up
- 3 and 6 months
Main finding
As reported in the abstract
| Group | Value | Mmol/mol |
|---|---|---|
| Baseline | 7.7% | 60.2 |
| 3 months | 7.1% | 54.4 |
| 6 months | 7.2% | 55.2 |
Value
Baseline7.7%
3 months7.1%
6 months7.2%
Mmol/mol
Baseline60.2
3 months54.4
6 months55.2
Observational data: associations, not effects.
Further findings
TIR (70-180 mg/dL) · 3 and 6 months
Time above range (TAR), time below range (TBR) and coefficient of variation (CV)
- Reductions in TAR, TBR and CV were observed
Original publication
Omnipod5 Real-World Data from the First Pediatric Users’ Universal Coverage Under the UK National Health Service. Diabetes Technol Ther. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →